The German Health Authority and the Belgian Federal Agency for Medicines and Health Products have approved CureVac AG’s Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection.
The trial will be conducted in Germany and
Belgium. CureVac’s mRNA vaccine candidate utilizes nucleotides without
chemical modifications and provides a strong and balanced activation of
the immune system. The mRNA encodes the full-length spike protein of
SARS-CoV-2 and is formulated with lipid nanoparticles.
The Phase 1 trial will include 168 healthy subjects between the ages of 18 to 60 and will target a dose range of 2 µg to 8 µg.
The aim is to determine the optimal dose, as well as to evaluate the safety and immune profile of the vaccine in humans.
https://seekingalpha.com/news/3583681-curevac-to-initiate-early-stage-trial-of-covidminus-19-vaccine-candidate-in-germany-and
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.